ALCMI-005: Phase II Study of Pembrolizumab and Epacadostat for Small Cell Lung Cancer After Previous Treatment With Platinum-Based Therapy
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 08 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 03 Oct 2018 Planned initiation date changed from 1 Aug 2018 to 1 Dec 2018.
- 31 Aug 2018 Biomarkers information updated